Literature DB >> 11716120

Detection of histidine rich protein 2 and panmalarial ICT Malaria Pf/Pv test antigens after chloroquine treatment of uncomplicated falciparum malaria does not reliably predict treatment outcome in eastern Indonesia.

E Tjitra1, S Suprianto, M E Dyer, B J Currie, N M Anstey.   

Abstract

In regions with drug-resistant malaria, the ability to rapidly detect or predict treatment failure (TF) soon after a course of standard therapy for Plasmodium falciparum malaria would facilitate the prompt institution of second-line therapy. We thus evaluated longitudinally the ability of the ICT Malaria Pf/Pv immunochromatographic test to predict treatment outcome. Sixty-six Sumbanese Indonesians with uncomplicated falciparum malaria were treated with chloroquine and followed for 28 days by use of 1997 World Health Organization criteria for assessment of therapeutic efficacy of antimalarial drugs. The ICT Pf/Pv testing could be compared with microscopy in approximately half of the patients on each day of follow-up. Although strongly positive histidine rich protein 2 (HRP2) line intensities (equal to or greater than the control band) in convalescence were highly predictive of TF, any degree of positivity for the HRP2 and panmalarial antigens in convalescence was only moderately predictive of TE Positive predictive values of the HRP2 and panmalarial antigens for TF were 76.9% and 87.0%, respectively, on Day 3, 82.4% and 87.5% on Day 7, and 78.9% and 78.9% on Day 14. Negative HRP2 and panmalarial antigen results in convalescence were even less predictive of an adequate clinical response, and false-negative HRP2 and panmalarial antigen test results were found in one-sixth (6 of 37) of recrudescent infections diagnosed by microscopy among patients with late treatment failure. To reliably predict treatment outcome with rapid antigen tests, further development appears necessary to improve sensitivity for viable asexual parasites while avoiding detection of both gametocytes and persistent antigen in convalescence.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11716120     DOI: 10.4269/ajtmh.2001.65.593

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  11 in total

1.  Salivary sIg-A response against the recombinant Ag38 antigen of Mycobacterium tuberculosis Indonesian strain.

Authors:  Tri Yudani Mardining Raras; Gamal Sholeh; Diana Lyrawati
Journal:  Int J Clin Exp Med       Date:  2014-01-15

2.  Accuracy of two malaria rapid diagnostic tests (RDTS) for initial diagnosis and treatment monitoring in a high transmission setting in Uganda.

Authors:  Phoebe Mbabazi; Heidi Hopkins; Emmanuel Osilo; Michael Kalungu; Pauline Byakika-Kibwika; Moses R Kamya
Journal:  Am J Trop Med Hyg       Date:  2015-01-26       Impact factor: 2.345

3.  Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations.

Authors:  Emiliana Tjitra; Joanne Baker; Sri Suprianto; Qin Cheng; Nicholas M Anstey
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

Review 4.  Rapid diagnostic tests for diagnosing uncomplicated P. falciparum malaria in endemic countries.

Authors:  Katharine Abba; Jonathan J Deeks; Piero Olliaro; Cho-Min Naing; Sally M Jackson; Yemisi Takwoingi; Sarah Donegan; Paul Garner
Journal:  Cochrane Database Syst Rev       Date:  2011-07-06

Review 5.  Rapid diagnostic tests for diagnosing uncomplicated non-falciparum or Plasmodium vivax malaria in endemic countries.

Authors:  Katharine Abba; Amanda J Kirkham; Piero L Olliaro; Jonathan J Deeks; Sarah Donegan; Paul Garner; Yemisi Takwoingi
Journal:  Cochrane Database Syst Rev       Date:  2014-12-18

6.  Accuracy of malaria rapid diagnosis test Optimal-IT(®) in Kinshasa, the Democratic Republic of Congo.

Authors:  Hypolite Mavoko Muhindo; Gillon Ilombe; Ruth Meya; Patrick M Mitashi; Albert Kutekemeni; Didier Gasigwa; Pascal Lutumba; Jean-Pierre Van Geertruyden
Journal:  Malar J       Date:  2012-07-06       Impact factor: 2.979

7.  Diagnostic performance of CareStart™ malaria HRP2/pLDH (Pf/pan) combo test versus standard microscopy on falciparum and vivax malaria between China-Myanmar endemic borders.

Authors:  Sun Xiaodong; Ernest Tambo; Wei Chun; Cheng Zhibin; Deng Yan; Wang Jian; Wang Jiazhi; Zhou Xiaonong
Journal:  Malar J       Date:  2013-01-07       Impact factor: 2.979

8.  Optimizing the HRP-2 in vitro malaria drug susceptibility assay using a reference clone to improve comparisons of Plasmodium falciparum field isolates.

Authors:  Wiriya Rutvisuttinunt; Suwanna Chaorattanakawee; Stuart D Tyner; Paktiya Teja-Isavadharm; Youry Se; Kritsanai Yingyuen; Panjaporn Chaichana; Delia Bethell; Douglas S Walsh; Chanthap Lon; Mark Fukuda; Duong Socheat; Harald Noedl; Kurt Schaecher; David L Saunders
Journal:  Malar J       Date:  2012-09-13       Impact factor: 2.979

9.  An interactive model for the assessment of the economic costs and benefits of different rapid diagnostic tests for malaria.

Authors:  Yoel Lubell; Heidi Hopkins; Christopher J M Whitty; Sarah G Staedke; Anne Mills
Journal:  Malar J       Date:  2008-01-28       Impact factor: 2.979

10.  Integrated community case management of fever in children under five using rapid diagnostic tests and respiratory rate counting: a multi-country cluster randomized trial.

Authors:  David Mukanga; Alfred B Tiono; Thomas Anyorigiya; Karin Källander; Amadou T Konaté; Abraham R Oduro; James K Tibenderana; Lucas Amenga-Etego; Sodiomon B Sirima; Simon Cousens; Guy Barnish; Franco Pagnoni
Journal:  Am J Trop Med Hyg       Date:  2012-11       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.